Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Moleculin Biotech Inc
MBRX | US
1.96
USD-0.12
-5.77%
MBRX | US
Loading StockChartView...
About Moleculin Biotech Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
1.96
Open
2.03
High
2.21
Low
1.79
Moleculin Biotech Inc. a clinical stage pharmaceutical company focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors as well as pancreatic cancer and other malignancies. It is also developing WP1220 an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston Texas.
View LessMBRX | US
Risk
170.0
Sharpe
-0.73
Luna's Score
39/100
Recommendation
Sell
Luna says (MBRX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
74.2%1 month
170.0%3 months
130.7%6 months
114.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.42
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
0.52
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-27.60M
MarketCap
5.58M
MarketCap(USD)
5.58M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-86.82
Short ratio
4.17
Short perc.
6.23
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.89
Range1M
3.51
Range3M
6.19
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.70
Price X volume
909.27K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.52 | 0.53 | Par |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.42 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 130.68 | 72.80 | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 5.58M | 3.66B | Emerging |
